Komori
Monthly4880CellSource Co.,Ltd.Pharmaceuticals

Preliminary Monthly KPI Report for September of the Fiscal Year Ending October 2026

The average number of outsourced processing cases per day in September was 50.2, slightly below the same month last year. By medical specialty, processing cases for orthopaedic practices specializing in private-pay treatment declined, while those for hybrid orthopaedic practices, obstetrics and gynecology practices, and aesthetic practices increased.

Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
50.2
orders/day
Wording
Conditional
How definitive the wording is.

Sales for this month

September 2026Fiscal year ending October 2026
Year-on-year change by component
Cosmetic medicine
+47.6%
Obstetrics and gynecology clinics
+18.9%
Self-pay orthopedic clinics
-9.5%
Hybrid orthopedic clinics
+4.6%
The bars use a logarithmic scale. This allows the relative sizes of the other items to be read even when one item is much larger than the others.
Key KPI year-on-year change
Number of blood-derived processing orders accepted from self-pay orthopedic clinics
-9.5%
Number of blood-derived processing orders accepted from hybrid orthopedic clinics
+4.6%
Monthly Commentary

The average number of outsourced processing cases per day in September was slightly below the same month last year. By medical specialty, processing cases for orthopaedic practices specializing in private-pay treatment declined, while those for other specialties increased.

Factors Affecting the Change

Blood-derived outsourced processing cases for orthopaedic practices specializing in private-pay treatment declined by 64 cases year on year, Processing cases for hybrid orthopaedic practices increased by 29 cases, Processing cases for obstetrics and gynecology practices increased by 18 cases, Processing cases for aesthetic practices increased by 10 cases, Utilization-promotion initiatives for hybrid orthopaedic practices took effect, Group 2 benefited from its revamped KPI strategy introduced this fiscal year

Measures from the following month onward

Continue strengthening the operating structure through the management support business for medical corporations, Expand the medium- to long-term order base for hybrid orthopaedic practices, Deploy sales resources in Group 1 to lift order volumes, Provide support for launching new partner clinics and promote utilization in Group 2

Scope of aggregation: Standalone (CellSource Co.,Ltd.'s outsourced processing services)

Sales for this month
ItemDetails
Month CoveredSeptember 2026
Fiscal Year CoveredFiscal year ending October 2026
Scope of aggregationStandalone (CellSource Co.,Ltd.'s outsourced processing services)
Year-on-year change by categoryName Self-pay orthopedic clinics / Year on year 90.5, Name Hybrid orthopedic clinics / Year on year 104.6, Name Obstetrics and gynecology clinics / Year on year 118.9, Name Cosmetic medicine / Year on year 147.6
Key KPIsIndicator name Average number of processing orders accepted per day / Value 50.2 orders/day / Year on year Slightly below the same month of the previous year, Indicator name Number of blood-derived processing orders accepted from self-pay orthopedic clinics / Value 613 Engagements / Year on year 90.5 Engagements, Indicator name Number of blood-derived processing orders accepted from hybrid orthopedic clinics / Value 664 Engagements / Year on year 104.6 Engagements, Indicator name Number of Group 2 orders / Value 1,217 Engagements / Year on year Increased compared with the same period of the previous year
Monthly CommentaryThe average number of outsourced processing cases per day in September was slightly below the same month last year. By medical specialty, processing cases for orthopaedic practices specializing in private-pay treatment declined, while those for other specialties increased.
Factors Affecting the ChangeBlood-derived outsourced processing cases for orthopaedic practices specializing in private-pay treatment declined by 64 cases year on year, Processing cases for hybrid orthopaedic practices increased by 29 cases, Processing cases for obstetrics and gynecology practices increased by 18 cases, Processing cases for aesthetic practices increased by 10 cases, Utilization-promotion initiatives for hybrid orthopaedic practices took effect, Group 2 benefited from its revamped KPI strategy introduced this fiscal year
Measures from the following month onwardContinue strengthening the operating structure through the management support business for medical corporations, Expand the medium- to long-term order base for hybrid orthopaedic practices, Deploy sales resources in Group 1 to lift order volumes, Provide support for launching new partner clinics and promote utilization in Group 2
Items this document does not state (14)
Net sales for the monthYear-on-year change in monthly net salesTotal-store sales, year on yearSame-Store Sales, Year on YearYear-on-Year Change in Customer CountYear-on-Year Change in Average Spend per CustomerCumulative Sales from Start of PeriodCumulative Year-on-Year Change from Start of PeriodSales by categoryNumber of Stores at Period-EndNumber of stores opened during the monthNumber of stores closed during the monthMonthly trend for the same period last yearNext Scheduled Disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Processing cases for orthopaedic practices specializing in private-pay treatment declined year on year. Cases for hybrid orthopaedic practices increased as utilization-promotion initiatives took effect, while Group 2 increased with the contribution of its revamped KPI strategy introduced this fiscal year. For orthopaedic practices specializing in private-pay treatment, the Company continues to strengthen its operating structure through its management support business for medical corporations, which began in the previous fiscal year.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Preliminary Monthly KPI Report for September of the Fiscal Year Ending October 2026 | CellSource Co.,Ltd. (4880) timely disclosure | Komori